NCT06405152 | RECRUITING | Macrophage Activation Syndrome

Assessment of Macrophage Activation syndromE in STill's Disease

Sponsor:

Swedish Orphan Biovitrum

Brief Summary:

Assessment of Macrophage activation syndrome in STill's disease: retrospective chart analysis of patient History, Symptom resolution and Treatment characteristics

Condition or disease

Macrophage Activation Syndrome

Still's Disease, Adult-Onset

Stills Disease, Juvenile-Onset

Intervention/treatment

Chart review

Detailed Description:

This is an observational, retrospective cohort study on the treatment utilization and outcomes of Macrophage Activation Syndrome (MAS) refractory to glucocorticoids (GC) in patients with Still's disease. The study will be conducted entirely through medical chart abstraction; all data will be taken from the patient's medical record, with no additional assessments.

Study Type :	OBSERVATIONAL
Estimated Enrollment :	80 participants
Official Title :	Assessment of Macrophage Activation syndromE in STill's Disease: Retrospective Chart Analysis of Patient HistorY, Symptom Resolution and Treatment Characteristics
Actual Study Start Date :	2023-09-27
Estimated Primary Completion Date :	2024-09-19
Estimated Study Completion Date :	2024-09-19

Information not available for Arms and Intervention/treatment

Ages Eligible for Study:	6 Months to 80 Years
Sexes Eligible for Study:	ALL
Accepts Healthy Volunteers:

Criteria

Inclusion Criteria

* Age \>6 months and ≤80 years at the beginning of the index MAS episode.
* Diagnosis of Still's disease (sJIA (systemic Juvenile Idiopathic Arthritis) or AOSD (Adult Onset Stills Disease) diagnosis).
* Diagnosis of MAS according to treating physician in the medical record.
* Patients who have received at least 3 consecutive days of GC after diagnosis of MAS and/or are judged by the Investigator to be refractory to GC due to clinical worsening of patient's condition .
* The onset of the index MAS episode occurred between 01 January 2012 and 30 September 2022.

Exclusion Criteria

* A diagnosis of primary Hemophagocytic Lymphohistiocytosis (HLH) prior to the beginning of the index MAS episode.
* Confirmed malignancy prior to the beginning of the index MAS episode.
* Patient treated with any investigational product as a part of clinical trial during the index MAS episode.

How to Participate

Want to participate in this study, select a site at your convenience, send yourself email to get contact details and prescreening steps.